Zogenix Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
20. Dezember 2013 16:15 ET
|
Zogenix
SAN DIEGO, Dec. 20, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
Zogenix Appoints Chief Medical Officer and Expands Medical Leadership Team
17. Dezember 2013 08:30 ET
|
Zogenix
SAN DIEGO, Dec. 17, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
Zogenix Reports Granting of Inducement Awards
11. Dezember 2013 07:30 ET
|
Zogenix
SAN DIEGO, Dec. 11, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
Zogenix Announces FDA Approval of 4 mg SUMAVEL(R) DosePro(R) (sumatriptan injection) Needle-Free Delivery System
10. Dezember 2013 08:30 ET
|
Zogenix
SAN DIEGO, Dec. 10, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders...
Zogenix to Present at the Oppenheimer 24th Annual Healthcare Conference
04. Dezember 2013 07:30 ET
|
Zogenix
SAN DIEGO, Dec. 4, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system...
Zogenix and Battelle Expand DosePro Technology Business Agreement
03. Dezember 2013 07:30 ET
|
Zogenix
SAN DIEGO and COLUMBUS, Ohio, Dec. 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) and Battelle today announced that they have entered into a new long-term collaborative agreement regarding...
Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters
12. November 2013 16:30 ET
|
Zogenix
SAN DIEGO, Nov. 12, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
Zogenix Prices Public Offering of Common Stock
05. November 2013 19:50 ET
|
Zogenix
SAN DIEGO, Nov. 5, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
Zogenix Announces Proposed Public Offering of Common Stock
04. November 2013 06:51 ET
|
Zogenix
SAN DIEGO, Nov. 4, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
Zogenix Reports Third Quarter 2013 Financial Results
04. November 2013 06:00 ET
|
Zogenix
Business Highlights and Milestones
Received FDA Approval for Zohydro™ ER (hydrocodone bitartrate), an extended-release oral formulation of hydrocodone without acetaminophen
Announced...